Relief of dysphagia · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
Good compliance · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in good compliance compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Length of hospital stay · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
Death associated with fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in death associated with fungal infection compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Patient quality of life · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
Amount of analgesia · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
Relief of pain · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
Change in disability score · children with SMA types II and III
1 finding from 1 review
Muscle strength · children with SMA types II and III
1 finding from 1 review
Acquiring the ability to stand or walk · children with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in quality of life · children with SMA types II and III
1 finding from 1 review
Change in pulmonary function · children with SMA types II and III
1 finding from 1 review
Change in disability score · non‐ambulatory children and adolescents with SMA types II and III
4 findings from 1 review
no estimate extracted
1 study · 160 participants
Very low
no estimate extracted
1 study · 160 participants
Very low
RR 1.43
1 study · 160 participants
Very low
Show 1 more finding
Muscle strength · non‐ambulatory children and adolescents with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acquiring the ability to stand or walk · non‐ambulatory children and adolescents with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in quality of life · non‐ambulatory children and adolescents with SMA types II and III
1 finding from 1 review
Change in pulmonary function · non‐ambulatory children and adolescents with SMA types II and III
1 finding from 1 review
Recurrent seizure at 6 months · children with febrile seizures
Continuous oral valproate showed no clear difference in recurrent seizure at 6 months compared with placebo or no treatment (low certainty).
1 finding from 1 review
Recurrent seizure at 12 months · children with febrile seizures
Continuous oral valproate showed no clear difference in recurrent seizure at 12 months compared with placebo or no treatment (low certainty).
1 finding from 1 review
Recurrent seizure at 18 months · children with febrile seizures
It is very uncertain whether continuous oral valproate changes recurrent seizure at 18 months compared with placebo or no treatment (very low certainty).
1 finding from 1 review